This article was originally distributed via PRWeb. PRWeb, WorldNow and this Site make no warranties or representations in connection therewith.
SOURCE: OTC Stock Picks
http://www.otcstockpicks.net Newsletter Announces Alert On Past Awesome Penny Stock Pick Hemispherx Biopharma
Stamford, CT (PRWEB) October 05, 2012
OTC Stock Picks updates investors today on Hemispherx Biopharma, and its drug candidate Ampligen.
As investors will recall from the September 24, 2012 Hemispherx press release, the U.S. Food and Drug Administration ("FDA") tentatively scheduled an Advisory Committee meeting to discuss the Ampligen New Drug Application for Chronic Fatigue Syndrome, which is currently under review by the FDA. The date of the Advisory Committee review has been tentatively set for December 20, 2012.
As previously announced, the Prescription Drug User Fee Act ("PDUFA") review goal for the FDA to complete its review is February 2, 2013.
With the now tentative up-coming Advisory Committee Meeting scheduled for December, the timeline for investors who want to bet on Hemispherx and Ampligen has shortened.
If Ampligen is well-received by the Advisory Committee, it could be the ‘tell’ for potential approval. Of course, the opposite is true as well. The FDA often makes decisions based on its Advisory Committee recommendations, but not always.
Hemispherx shares have shown weakness as of late, with a 20% pullback off the $1.00 9/21/12 close.
If approved, shares could see much higher prices than current levels. Continue to watch if share prices stay flat, or weaken over the next few weeks for potential opportunities.
Hemispherx announced on August 14, 2012 that the FDA Accepted the company’s Complete Response Submission Regarding Ampligen New Drug Application for Chronic Fatigue Syndrome.
Ampligen is a synthetic specifically configured double-stranded RNA containing regularly occurring regions of mismatching. Ampligen and Oragens experimental nucleic acids are being developed for the potential treatment of globally important viral diseases and disorders of the immune system including HPV, HIV, Chronic Fatigue Syndrome, Hepatitis and influenza.
In March of 2012, Hemispherx published phase III double-blind trial results for Ampligen and concluded that the compound produced objective improvement in ET(exercise tolerance) and a reduction in Chronic fatigue syndrome/myalgic encephalomyelitis related concomitant medication usage as well as other secondary outcomes in patients who have Chronic Fatigue Syndrome. The drug was also generally well-tolerated by patients. (Trial Registration: ClinicalTrials.gov NCT00215800).
The team is among the US market leaders in connecting penny stocks to investors. With over two decades of market experience, the team prides itself on having the ‘pulse’ of the penny stock market.
The company tracks over 100 stocks with the goal of bringing traders attention to stock momentum changes and trading opportunities. The team is exceptional at predicting momentum-changes in stocks via technical analysis, and fundamentals, and then swiftly relaying this information through its penny stock newsletters.
The team is reliable and steady resource for finding penny stocks in the market, and uses the latest technologies, websites and social media outlets to skillfully amass and communicate stock information.
Disclaimer: OTC Stock Picks is not a registered securities advisor. Investors should always conduct their own additional due diligence with any potential investment or highlighted company. OTC Stock Picks provides updates on selected stocks via press releases, newsletters, and company website, but this should not be construed as a recommendation to buy or sell. Please visit http://www.otcstockpicks.net for a more complete list of risks and disclosures.
For the original version on PRWeb visit: http://www.prweb.com/releases/prwebawesome/pennystocks/prweb9977577.htm